Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Mirum Pharmaceuticals, Inc. < Previous 1 2 3 4 5 Next > Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics July 17, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM TVTX Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 10, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress June 23, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Event-Free Survival Data from Mirum’s LIVMARLI Alagille Syndrome Program Published in Hepatology June 14, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 09, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress June 07, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting May 19, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing Cholangitis May 18, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting May 17, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study May 11, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update May 04, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023 April 27, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering April 13, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering April 12, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results April 12, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 10, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors April 06, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis April 05, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older March 14, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 10, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update March 08, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023 March 01, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis February 14, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 10, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference February 09, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 10, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates January 09, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 January 03, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors December 19, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.